Cytokinetics' heart failure drug improves exercise capacity, sending shares soaring in long-awaited win

Cytokinetics’ Christmas wish has come true. Cardiomyopathy treatment aficamten has improved exercise capacity in a pivotal phase 3 trial, sending the biotech’s shares soaring by more than 50% in pre-market trading Wednesday.